The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
Category: Centers for Medicare and Medicaid Services
-
F.D.A. Approves New Treatment for Early Alzheimer’s
The New York Times – Business: -
U.S. Health Officials Seek New Curbs on Private Medicare Advantage Plans
The New York Times – Business:Proposed regulations would crack down on misleading ads for the private plans and would enhance scrutiny of denials for coverage of medical care.
-
A Rural Hospital’s Excruciating Choice: $3.2 Million a Year or Inpatient Care?
The New York Times – Business:A new federal program offers hefty payments to small hospitals at risk of closing. But it comes with a bewildering requirement: to end all inpatient care.
-
Expect Higher Health Insurance Premiums, but Not a Lot Higher
The New York Times – Business:Benefit costs may go up as much as 6 percent. Wary of driving workers away, many employers may not pass on the full increases, analysts say.